"Novo Nordisk A/S (NVO) is a Danish pharmaceutical company that focuses on diabetes care and biopharmaceuticals," notes Nicholas Vardy.

The editor of the Global Bull Market Alert explains, "Novo Nordisk is a quiet giant, employing 30,000 people in 76 countries; we think investors could double their money with this profit machine.

"More than 200 million people worldwide suffer from some form of diabetes. Patients with type 1 (juvenile) diabetes can't make insulin at all and need to inject it their whole lives.

Continue reading Novo Nordisk A/S (NVO): Health Care 'Profit Machine'

Novo Nordisk A/S (NVO): Health Care 'Profit Machine' originally appeared on BloggingStocks on Wed, 23 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Edwards Lifesciences: A Heart-Felt Buy

Edwards Lifesciences: A Heart-Felt Buy originally appeared on BloggingStocks on Thu, 17 Feb 2011 10:00:00 EST. Please see our terms for use of feeds.

"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.

The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.

"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.

Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety originally appeared on BloggingStocks on Tue, 08 Feb 2011 11:00:00 EST. Please see our terms for use of feeds.

This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"For over 50 years, Medtronic (MDT) has been the premier medical device manufacturer in the marketplace," notes Jim Stack.

The money manager and editor of InvesTech Market Analyst explains, "With the invention of the battery-powered pacemaker in the mid 1950s, Medtronic began a long string of technological innovations.

Continue reading Top Picks 2011: Medtronic (MDT)

Top Picks 2011: Medtronic (MDT) originally appeared on BloggingStocks on Tue, 04 Jan 2011 13:00:00 EST. Please see our terms for use of feeds.

"After releasing their 3Q financials. the stock price at Isis Pharmacueticals (ISIS) perked up as their large cash position and deep pipeline have attracted some new investors," notes biotech expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "When investors investigate the ISIS story and all its parts, they come away with an appreciation for all the potential long-term value being created at the company.

Continue reading Isis (ISIS): 'Deep Pipeline, Long-Term Value'

Isis (ISIS): 'Deep Pipeline, Long-Term Value' originally appeared on BloggingStocks on Fri, 17 Dec 2010 13:00:00 EST. Please see our terms for use of feeds.

"I love going to health care conferences, where companies often reveal new technologies, groundbreaking drugs, or novel ways of attacking diseases," says Marc Lichtenfeld.

The contributing editor to Investment U explains, "Here's a review of four interesting presentations I recently saw at LifeTech Capital's small-cap health care conference in Miami: Inovio Pharmaceuticals (INO), Nabi Pharmaceuticals (NABI), NeoStem (NBS), and Oculus Innovative Sciences (OCLS).

Continue reading Health Care Conference Highlights Speculative Innovators

Health Care Conference Highlights Speculative Innovators originally appeared on BloggingStocks on Tue, 23 Nov 2010 13:00:00 EST. Please see our terms for use of feeds.

"Myriad Genetics (MYGN) is an innovative company that can diagnose your risk of cancer years before you have any symptoms," notes growth stock expert Lou Basenese.

The editor of White Cap Research explains, "Even better, it benefits from no competition and one of the best research and development teams around.

"Myriad Genetics' main product is called BRACAnalysis, which is a test that analyzes a woman's genetics to determine her likelihood of developing breast and ovarian cancers. Plain and simple, the test saves lives ... and money.

Continue reading Myriad Genetics (MYGN): Speculating on Cancer Diagnosis

Myriad Genetics (MYGN): Speculating on Cancer Diagnosis originally appeared on BloggingStocks on Fri, 19 Nov 2010 13:00:00 EST. Please see our terms for use of feeds.

Cardinal Health's shares (CAH), first discussed here on April 27, 2009, at a pre-spin-off price of $34.22, continued to meander over the past four months, but I still like the business model at this juncture. Here's why.

Cardinal probably will post a 3% to 5% 2010 revenue rise, followed by a 2% to 4% increase in 2011.

Key operation factors working in CAH's favor include increased prescription sales, modest pricing power, better performance of wider-margin generic drugs, lower customer attrition, and more-effective cost controls. Cardinal's medical unit, however, will lag other divisions, due to soft hospital markets.

Continue reading Cardinal Health Is Trying Investors' Patience

Cardinal Health Is Trying Investors' Patience originally appeared on BloggingStocks on Wed, 17 Nov 2010 17:30:00 EST. Please see our terms for use of feeds.

"Two of our long-standing buy recommendations are involved in selling products and services for the genetic research market: Affymetrix (AFFX) and Illumina (ILMN)," notes biotech and growth stock specialist Nate Pile.

The editor of Nate's Notes explains, "In a nutshell, both of these companies have developed technologies that allow researchers to do what is known as 'high-throughput genetic screening'.

"And, while the two companies are direct competitors in many of the markets in which they compete, we believe that both stocks should be bought at the current time.

Continue reading Genetic Gains? Affymetrix (AFFX) and Illumina (ILMN)

Genetic Gains? Affymetrix (AFFX) and Illumina (ILMN) originally appeared on BloggingStocks on Tue, 21 Sep 2010 10:20:00 EST. Please see our terms for use of feeds.

"President Obama's push into digital medical records could lead to a profit surge for Quality Systems (QSII)," says Andy Obermueller, an adviser who specializes in analyzing the investment opportunities related to new government programs and legislation.

The editor of Government-Driven Investing explains, "Better access to records will show doctors a more complete view of their patients, reduce error and prevent redundant tests.

"In my view, it is not a question of if medical service providers are going to buy these system, it's a question of when. And the cost savings of digital medical records could be significant.

Continue reading Digital Medical Records Boost Quality Systems (QSII)

Digital Medical Records Boost Quality Systems (QSII) originally appeared on BloggingStocks on Fri, 17 Sep 2010 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Johnson & Johnson (JNJ) : 'Dirt Cheap Valuation'

Johnson & Johnson (JNJ) : 'Dirt Cheap Valuation' originally appeared on BloggingStocks on Tue, 29 Jun 2010 10:00:00 EST. Please see our terms for use of feeds.

He continues, "As the name of our 2-for-1 Stock Split Newsletter suggests, the stocks within our model portfolio are exclusively chosen from among those companies that have just recently announced 2 for 1 stock splits.

Continue reading Core Labs (CLB): A 'Core' Pick Among Stock Splits

Core Labs (CLB): A 'Core' Pick Among Stock Splits originally appeared on BloggingStocks on Fri, 26 Mar 2010 15:20:00 EST. Please see our terms for use of feeds.

Continue reading Sirus XM (SIRI): An Underappreciated Monopoly

Sirus XM (SIRI): An Underappreciated Monopoly originally appeared on BloggingStocks on Fri, 12 Mar 2010 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Biotech Expert Eyes Isis Pharmaceuticals (ISIS)

Biotech Expert Eyes Isis Pharmaceuticals (ISIS) originally appeared on BloggingStocks on Fri, 12 Mar 2010 12:00:00 EST. Please see our terms for use of feeds.

Continue reading Becton Dickinson Breaks Through Resistance

Becton Dickinson Breaks Through Resistance originally appeared on BloggingStocks on Mon, 11 Jan 2010 15:30:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Mindray Medical International Limited (MR), a China-based medical devices firm, is our top investment idea for the coming year," says Alan Newman.

In his CrossCurrents newsletter, he notes, "The company is headquartered in Shenzhen, China, and is one of many Chinese companies now specializing in the development, manufacture and marketing of medical devices worldwide.

Continue reading Top Picks for 2010: Mindray Medical (MR)

Top Picks for 2010: Mindray Medical (MR) originally appeared on BloggingStocks on Fri, 08 Jan 2010 16:15:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

J. Royden Ward is the editor of The Cabot Benjamin Graham Value Letter, a newsletter that -- as its name suggests -- focuses on stocks that meet the criteria of legendary value investor Ben Graham.

For his top pick for 2010, he the advisor looks to Amedisys (AMED), a provider of home health care and hospice services.

Continue reading Top Picks for 2010: Amedisys (AMED)

Top Picks for 2010: Amedisys (AMED) originally appeared on BloggingStocks on Wed, 06 Jan 2010 16:00:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"My top stock pick for 2010 is MannKind Corp. (MNKD), which is developing a a novel formulation of inhalable insulin called Afresa," notes Nate Pile.

In his Nate's Notes newsletter, he explains, "I would emphasize that while the stock must be considered speculative until the FDA delivers a ruling in mid-January of next year, I believe the clinical data that has been submitted by the company is likely to warrant approval."

Continue reading Top Picks for 2010: MannKind (MNKD)

Top Picks for 2010: MannKind (MNKD) originally appeared on BloggingStocks on Tue, 05 Jan 2010 14:00:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Medical equipment giant Becton, Dickinson and Co. (BDX) is our top investment pick for the coming year," says Jonas Elmerraji. Here's his review from the advisor's Rhino Stock Report.

"If anything's certain for 2010, it'll be that nothing's certain as far as stocks are concerned. With a substantial rally that's pushed the valuations of major indexes like the S&P 500 and Dow more than 60% higher since mid-March lows, it's inevitable for investor anxiety to spill over into the New Year.

Continue reading Top Picks for 2010: Becton, Dickinson (BDX)

Top Picks for 2010: Becton, Dickinson (BDX) originally appeared on BloggingStocks on Mon, 28 Dec 2009 17:00:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"My number one stock pick to start 2010 is Medifast Inc. (MED), a weight and disease management company," says Mike Turner.

The editor of Mastering the Markets explains, "The stock has skyrocketed from the $5 area to over $30 in just the last nine months." Despite the gains, the advisor remains bullish on the stock's prospects.

Continue reading Top Picks for 2010: Medifast (MED)

Top Picks for 2010: Medifast (MED) originally appeared on BloggingStocks on Mon, 28 Dec 2009 08:00:00 EST. Please see our terms for use of feeds.